Clinical Development Small Molecule Targeted Protein Degradation 
The Pharma Data
JUNE 12, 2025
Expanding Targeted Protein Degradation in Hematologic Malignancies Targeted protein degradation is a powerful therapeutic approach designed to destroy disease-driving proteins within cells, thereby inhibiting their ability to contribute to disease progression.
The Pharma Data
AUGUST 1, 2025
BGB-16673 is designed to degrade BTK proteins rather than merely inhibit them, offering a novel mechanism of action that could overcome resistance to currently available BTK inhibitors. BGB-16673 is the most advanced BTK protein degrader in the clinic, with an extensive global clinical development program.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 21, 2020
Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe.
The Pharma Data
SEPTEMBER 25, 2020
. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. Source link.
LifeSciVC
FEBRUARY 5, 2025
Lacking active sites entirely, transcription factors are instead largely regulated by post-translational modification, which in turn impacts changes in conformation, behavior, and interaction with other proteins.
Expert insights. Personalized for you.
Let's personalize your content